Microbiology & Infectious Diseases

Carbapenem-resistant Enterobacterales infections are on the rise across Europe, with experts warning of worsening transmission and increasing resistance.

Pseudomonas aeruginosa infection drives lung transplant rejection by inducing regulatory T cell death and promoting B cell responses.

The NHS has expanded its mpox vaccination programme across England, opening 12 new sites to improve access for those at higher risk of infection.

A new clinical practice guideline for well-appearing febrile infants has led to a reduction in hospitalisations, antibiotic use, and invasive procedures.

Individuals who experience multiple COVID-19 infections are at greater risk of developing post-acute sequelae of COVID-19.

Research has identified microRNAs as potential biomarkers for predicting COVID-19-related mortality in patients with cancer.

Nasal microbiota transplantation could revolutionise the treatment of chronic rhinosinusitis and respiratory tract infections.

Aztreonam–avibactam is a promising treatment for complicated intra-abdominal infections and hospital-acquired or ventilator-associated pneumonia caused by Gram-negative bacteria.

Elevated uric acid levels in children with severe malaria are associated with significantly increased risks of death and long-term cognitive impairment.

A novel clinical decision support system, TBorNotTB, has been developed to assist clinicians in diagnosing pulmonary tuberculosis in low-prevalence settings.

Women are at a significantly higher risk of developing long COVID compared to men, especially between the ages of 40–55 years.

The CROSS score has been developed to accurately predict the risk of intensive care unit admission for patients with COVID-19 who present at the emergency room.

A decade-long study has shed light on the risks of hepatitis D virus superinfection in people with HIV co-infected with hepatitis B virus.

Research reveals that 15% of children aged 0–35 months in the USA received at least one invalid vaccine dose between 2011–2020.

The ongoing RECOVER-Adult study reveals that myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) develops significantly more frequently following SARS-CoV-2 infection.

Using a procalcitonin-guided algorithm does not significantly reduce duration of IV antibiotic treatment in children with bacterial infections.